Journal of Clinical Oncology, Vol 16, 3216-3221, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?

C Ripamonti, L Groff, C Brunelli, D Polastri, A Stavrakis and F De Conno
Pain Therapy and Palliative Care Division, National Cancer Institute, Milan, Italy. tdpint@tin.it

PURPOSE: To define the dose ratio between morphine and methadone in relation to the previous morphine dose and the number of days needed to achieve the same level of analgesia in a group of patients with advanced cancer with pain who switched from morphine to oral methadone. PATIENTS AND METHODS: A cross-sectional prospective study of 38 consecutive cancer patients who switched from morphine to oral methadone was performed. The intensity of pain before, during, and after the switching period was assessed through a four-point verbal Likert scale. The relationship between previous morphine dose and the final equianalgesic methadone dose, dose ratio between morphine and methadone, and the number of days required to achieve equianalgesia have been examined by means of Pearson's correlation coefficient, scatter plots, and Cuzick's test for trend respectively. RESULTS: Before the switch, the median oral equivalent daily dose of morphine was 145 mg/d; after the switch, the median equianalgesic oral methadone dose was 21 mg/d. A median time of 3 days (range, 1 to 7 days) was necessary to achieve the equianalgesia with oral methadone; the lower the preswitching morphine dose, the fewer days necessary to achieve equianalgesia with oral methadone (P < .001). Dose ratios ranged from 2.5:1 to 14.3:1 (median, 7.75:1), which indicated that, in most cases, the dose ratio was much higher than that suggested by the published equianalgesic tables. A strong linear positive relationship between morphine and methadone equianalgesic doses was obtained (Pearson's correlation coefficient, 0.91). The dose ratio increased with the increase of the previous morphine dose with a much higher increase at low morphine doses. CONCLUSION: The results of our study confirm that methadone is a potent opioid, more potent than believed. Caution is recommended when switching from any opioid to methadone, especially in patients who are tolerant to high doses of opioids.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				V. Kharlamb Important lessons in opioid selection Am. J. Health Syst. Pharm., September 1, 2008; 65(17): 1600 - 1601. [Full Text] [PDF]

				V. Kharlamb and H. Kourlas Edema in a patient receiving methadone for chronic low back pain Am. J. Health Syst. Pharm., December 15, 2007; 64(24): 2557 - 2560. [Abstract] [Full Text] [PDF]

				A. E Patanwala, J. Duby, D. Waters, and B. L Erstad Opioid Conversions in Acute Care Ann. Pharmacother., February 1, 2007; 41(2): 255 - 266. [Abstract] [Full Text] [PDF]

				O. M. S Fredheim, S. Kaasa, O. Dale, P. Klepstad, N. I. Landro, and P. C Borchgrevink Opioid switching from oral slow release morphine to oral methadone may improve pain control in chronic non-malignant pain: a nine-month follow-up study Palliative Medicine, January 1, 2006; 20(1): 35 - 41. [Abstract] [PDF]

				S. Mercadante, P. Ferrera, P. Villari, and A. Casuccio Rapid Switching Between Transdermal Fentanyl and Methadone in Cancer Patients J. Clin. Oncol., August 1, 2005; 23(22): 5229 - 5234. [Abstract] [Full Text] [PDF]

				S. Mercadante and E. Arcuri Hyperalgesia and opioid switching American Journal of Hospice and Palliative Medicine, July 1, 2005; 22(4): 291 - 294. [Abstract] [PDF]

				L. G. L. Soares Methadone for cancer pain: What have we learned from clinical studies? American Journal of Hospice and Palliative Medicine, May 1, 2005; 22(3): 223 - 227. [Abstract] [PDF]

				R Brown, C Kraus, M Fleming, and S Reddy Methadone: applied pharmacology and use as adjunctive treatment in chronic pain Postgrad. Med. J., November 1, 2004; 80(949): 654 - 659. [Abstract] [Full Text] [PDF]

				E. Bruera, J. L. Palmer, S. Bosnjak, M. A. Rico, J. Moyano, C. Sweeney, F. Strasser, J. Willey, M. Bertolino, C. Mathias, et al. Methadone Versus Morphine As a First-Line Strong Opioid for Cancer Pain: A Randomized, Double-Blind Study J. Clin. Oncol., January 1, 2004; 22(1): 185 - 192. [Abstract] [Full Text] [PDF]

				C. J Cornish and J. C Keen An alternative low-dose ad libitumschedule for conversion of other opioids to methadone Palliative Medicine, October 1, 2003; 17(7): 643 - 644. [PDF]

				D. M. Brundage Cancer Pain Management in Adults: A Pharmacist's Perspective Journal of Pharmacy Practice, August 1, 2003; 16(4): 284 - 290. [Abstract] [PDF]

				R. A. Indelicato and R. K. Portenoy Opioid Rotation in the Management of Refractory Cancer Pain J. Clin. Oncol., May 1, 2003; 21(90090): 87s - 91. [Full Text] [PDF]

				K. M. Foley Opioids and Chronic Neuropathic Pain N. Engl. J. Med., March 27, 2003; 348(13): 1279 - 1281. [Full Text] [PDF]

				D. M W Tse, M. M K Sham, D. K H Ng, and H M Ma An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population Palliative Medicine, March 1, 2003; 17(2): 206 - 211. [Abstract] [PDF]

				S. Watanabe, Y. Tarumi, D. Oneschuk, P. Lawlor, R. K. Portenoy, and R. A. Indelicato Opioid Rotation to Methadone: Proceed With Caution J. Clin. Oncol., May 1, 2002; 20(9): 2409 - 2410. [Full Text] [PDF]

				R. A. Indelicato and R. K. Portenoy Opioid Rotation in the Management of Refractory Cancer Pain J. Clin. Oncol., January 1, 2002; 20(1): 348 - 352. [Full Text] [PDF]

				S. Mercadante, A. Casuccio, F. Fulfaro, L. Groff, R. Boffi, P. Villari, V. Gebbia, and C. Ripamonti Switching From Morphine to Methadone to Improve Analgesia and Tolerability in Cancer Patients: A Prospective Study J. Clin. Oncol., June 1, 2001; 19(11): 2898 - 2904. [Abstract] [Full Text] [PDF]

				N. Cherny, C. Ripamonti, J. Pereira, C. Davis, M. Fallon, H. McQuay, S. Mercadante, G. Pasternak, and V. Ventafridda Strategies to Manage the Adverse Effects of Oral Morphine: An Evidence-Based Report J. Clin. Oncol., May 1, 2001; 19(9): 2542 - 2554. [Abstract] [Full Text] [PDF]

				R. E. Enck Switching to methadone American Journal of Hospice and Palliative Medicine, May 1, 2001; 18(3): 149 - 150. [PDF]

				F. Nauck, C. Ostgathe, and E. D. Dickerson A German model for methadone conversion American Journal of Hospice and Palliative Medicine, May 1, 2001; 18(3): 200 - 202. [PDF]

				M. Pappagallo, E. D. Dickerson, and S. Hulka Palliative care and hospice opioid dosing guidelines with breakthrough pain (BP) doses American Journal of Hospice and Palliative Medicine, November 1, 2000; 17(6): 407 - 413. [PDF]

				W. L. Wheeler and E. D. Dickerson Clinical applications of methadone American Journal of Hospice and Palliative Medicine, May 1, 2000; 17(3): 196 - 203. [PDF]

				D. Berland Pain Management in Patients with Advanced Cancer Ann Intern Med, April 4, 2000; 132(7): 593 - 593. [Full Text] [PDF]

				S. Mercadante, A. Casuccio, and L. Calderone Rapid Switching From Morphine to Methadone in Cancer Patients With Poor Response to Morphine J. Clin. Oncol., October 1, 1999; 17(10): 3307 - 3312. [Abstract] [Full Text] [PDF]

				J. L. Abrahm and for the ACP-ASIM End-of-Life Care Consensus Panel Management of Pain and Spinal Cord Compression in Patients with Advanced Cancer Ann Intern Med, July 6, 1999; 131(1): 37 - 46. [Abstract] [Full Text] [PDF]

				K. Foley A 44-Year-Old Woman With Severe Pain at the End of Life JAMA, May 26, 1999; 281(20): 1937 - 1945. [Full Text] [PDF]

				Opioid Treatment of Cancer Pain Journal Watch (General), October 23, 1998; 1998(1023): 2 - 2. [Full Text]